Gessel has advised Genomtec on a non-brokered public offering carried out under an accelerated book-building procedure and the related private placement of the company’s newly issued shares.
Genomtec is a technology company operating in the field of clinical diagnostics. It was founded in 2016 in Wroclaw, Poland.
According to Gessel, “the public offering included 1,237,000 series M new issue shares and 900,000 existing WSE-listed shares of the company offered by its shareholder Leonarto Funds SCSp. The shares offered by the shareholder were previously borrowed for this purpose from other shareholders of the company. The public offering was targeted at qualified investors and selected retail investors. As part of the private placement, the company issued 400,000 N shares, which were subscribed for by Leonarto Funds SCSp for the purpose of reinvesting the funds raised from the sale of the company’s shares in the public offering (including the funds allocated for the shareholder’s purchase of part of the M shares). The total value of the public offering and the private placement amounted to PLN 20.3 million.”
The Gessel team included Partner Krzysztof Marczuk, Managing Associate Michal Wielinski, Senior Associate Jakub Rowicki, and Associate Michal Dunikowski.
Gessel did not respond to our inquiry on the matter.
